Imatinib combined with myeloablative allogeneic hematopoietic stem cell transplantation for advanced phases of chronic myeloid leukemia

Leukemia Research

Volumn 35, Issue 10, 2011, Pages 1307-1311

  Luo, Yi ^a   Zhao, Yanmin ^a   Tan, Yamin ^a   Shi, Jimin ^a   Han, Xiaoyan ^a   Zheng, Yanlong ^a   Li, Li ^a   He, Jingsong ^a   Xie, Wanzhuo ^a   Ye, Xiujin ^a   Cai, Zhen ^a   Lin, Maofang ^a   Huang, He ^a  

^a ZHEJIANG UNIVERSITY   (China)

Author keywords

Advanced phase; Chronic myeloid leukemia; Imatinib; Myeloablative allogeneic stem cell transplantation; Response

Indexed keywords

BUSULFAN; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; IMATINIB; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER;

ACUTE GRAFT VERSUS HOST DISEASE; ADULT; ADVANCED CANCER; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CHRONIC GRAFT VERSUS HOST DISEASE; CHRONIC MYELOID LEUKEMIA; CLINICAL ARTICLE; CLINICAL EVALUATION; CONTROLLED STUDY; CYTOGENETICS; DOSE RESPONSE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; FEMALE; FOLLOW UP; HUMAN; LEUKEMIA RELAPSE; LEUKEMIA REMISSION; MALE; MYELOABLATIVE CONDITIONING; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; TREATMENT DURATION;

ADULT; BLAST CRISIS; BUSULFAN; COMBINED MODALITY THERAPY; CYCLOPHOSPHAMIDE; CYCLOSPORINE; DISEASE PROGRESSION; FEMALE; FOLLOW-UP STUDIES; GRAFT SURVIVAL; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MALE; METHOTREXATE; MIDDLE AGED; MYCOPHENOLIC ACID; MYELOABLATIVE AGONISTS; PIPERAZINES; PYRIMIDINES; REMISSION INDUCTION; SURVIVAL RATE; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, HOMOLOGOUS;

EID: 80052095260     PISSN: 01452126     EISSN: 18735835     Source Type: Journal    
DOI: 10.1016/j.leukres.2011.01.001     Document Type: Article

References (19)

1. Palandri F., Castagnetti F., Alimena G., et al. The long-term durability of cytogenetic responses in patients with accelerated phase chronic myeloid leukemia treated with imatinib 600mg: the GIMEMA CML Working Party experience after a 7-year follow-up. Haematologica 2009, 94(2):205-212.
2. Sawyers C.L., Hochhaus A., Feldman E., et al. Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study. Blood 2002, 99(10):3530-3539.
3. Baccarani M., Saglio G., Goldman J., et al. Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet. Blood 2006, 108(6):1809-1820.
4. Gratwohl A., Brand R., Apperley J., et al. Allogeneic hematopoietic stem cell transplantation for chronic myeloid leukemia in Europe 2006: transplant activity, long-term data and current results. An analysis by the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT). Haematologica 2006, 91(4):513-521.
5. Radich J.P., Gehly G., Gooley T., et al. Polymerase chain reaction detection of the BCR-ABL fusion transcript after allogeneic marrow transplantation for chronic myeloid leukemia: results and implications in 346 patients. Blood 1995, 85(9):2632-2638.
6. Stirewalt D.L., Guthrie K.A., Beppu L., et al. Predictors of relapse and overall survival in Philadelphia chromosome-positive acute lymphoblastic leukemia after transplantation. Biology Blood Marrow Transplant 2003, 9(3):206-212.
7. Luo Y., Lai X.Y., Tan Y.M., et al. Reduced-intensity allogeneic transplantation combined with imatinib mesylate for chronic myeloid leukemia in first chronic phase. Leukemia 2009, 23(6):1171-1174.
8. Thomas E.D., Storb R., Clift R.A., et al. Bone-marrow transplantation (second of two parts). The New England Journal of Medicine 1975, 292(17):895-902.
9. Cortes J., Kantarjian H. Advanced-phase chronic myeloid leukemia. Seminars in Hematology 2003, 40(1):79-86.
10. Lee S., Kim Y.J., Min C.K., et al. The effect of first-line imatinib interim therapy on the outcome of allogeneic stem cell transplantation in adults with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia. Blood 2005, 105(9):3449-3457.
11. Oehler V.G., Gooley T., Snyder D.S., et al. The effects of imatinib mesylate treatment before allogeneic transplantation for chronic myeloid leukemia. Blood 2007, 109(4):1782-1789.
12. Lee S.J., Kukreja M., Wang T., et al. Impact of prior imatinib mesylate on the outcome of hematopoietic cell transplantation for chronic myeloid leukemia. Blood 2008, 112(8):3500-3507.
13. Zaucha J.M., Prejzner W., Giebel S., et al. Imatinib therapy prior to myeloablative allogeneic stem cell transplantation. Bone Marrow Transplantation 2005, 36(5):417-424.
14. Visani G., Rosti G., Bandini G., et al. Second chronic phase before transplantation is crucial for improving survival of blastic phase chronic myeloid leukaemia. British Journal of Haematology 2000, 109(4):722-728.
15. Weisser M., Schleuning M., Haferlach C., et al. Allogeneic stem-cell transplantation provides excellent results in advanced stage chronic myeloid leukemia with major cytogenetic response to pre-transplant imatinib therapy. Leukemia & Lymphoma 2007, 48(2):295-301.
16. Wang H., Cheng F., Cuenca A., et al. Imatinib mesylate (STI-571) enhances antigen-presenting cell function and overcomes tumor-induced CD4+ T-cell tolerance. Blood 2005, 105(3):1135-1143.
17. Au W.Y., Caguioa P.B., Chuah C., et al. Chronic myeloid leukemia in Asia. International Journal of Hematology 2009, 89(1):14-23.
18. Zhao Y., Liu L., Wang Y., et al. Efficacy and prognosis of chronic myeloid leukemia treated with imatinib mesylate in a Chinese population. International Journal of Hematology 2009, 89(4):445-451.
19. Bacher U., Klyuchnikov E., Zabelina T., et al. The changing scene of allogeneic stem cell transplantation for chronic myeloid leukemia-a report from the German Registry covering the period from 1998 to 2004. Annals of Hematology 2009, 88(12):1237-1247.